The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor genotyping on the outcome of patients receiving HLA-matched sibling donor haematopoietic stem cell transplantation for myeloid malignancies

Swiss Medical Weekly

Volumn 143, Issue , 2013, Pages

  Wang, Hua ^a   He, Yi ^b   Zhai, Wen Jing ^b   Wang, Mei ^b   Zhou, Zheng ^b   Zhao, Ying Xin ^b   Feng, Si Zhou ^b   Han, Ming Zhe ^b  

^a YANTAI YUHUANGDING HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Haematopoietic stem cell transplantation; HLA Cw ligand; Killer immunoglobulin like receptor; Myeloid malignancy; Outcome

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ADULT; ARTICLE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; GENOTYPE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOTE; HLA MATCHING; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SIBLING; ADOLESCENT; ALLOTRANSPLANTATION; GENETICS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MORTALITY; RECURRENT DISEASE;

ADOLESCENT; ADULT; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOTE; HISTOCOMPATIBILITY TESTING; HLA-C ANTIGENS; HOMOZYGOTE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTORS, KIR; RECURRENCE; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84877700155     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2013.13717     Document Type: Article

References (32)

1. Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer immunoglobulin-like receptors. Mol Immunol. 2002;38(14):1007-21. (Pubitemid 34310440)
2. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 1995;181(3):1133-44.
3. Farag S, Fehniger T, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukaemia effect. Blood. 2002;100(6):1935-47. (Pubitemid 35001221)
4. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-100. (Pubitemid 34229476)
5. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor natural killer cell allorecognition of missing self in haploidentic-al hematopoietic transplantation for acute myeloid leukaemia: challenging its predictive value. Blood. 2007;110(1):433-40. (Pubitemid 47026866)
6. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172(1):644-50. (Pubitemid 38020523)
7. Bishara A, De Santis D, Witt CC, Christiansen FT, Or R, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens. 2004;63(3):204-11. (Pubitemid 38297254)
8. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after non myelo-ablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010;16(4):533-42.
9. Moretta A, Pende D, Locatelli F, Moretta L. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical hae-mopoietic stem cell transplantation to cure high-risk leukaemias. Clin Exp Immunol. 2009;157(3):325-31.
10. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, et al. Anti-leukaemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for paediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009;113(13):3119-29.
11. Schaffer M, Malmberg KJ, Ringdén O, Ljunggren HG, Remberger M. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation. 2004;78(7):1081-5. (Pubitemid 39391875)
12. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, et al. Missing KIR-ligands is associated with less relapse and increased graft versus host disease (GVHD) following unrelated donor allogeneic HCT. 2007;109(11):5058-61.
13. Gagne K, Busson M, Bignon JD, Loiseau P, Dormoy A, et al. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(11):1366-75.
14. Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Crad-dock CF, et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA identical sibling hematopoietic stem cell transplantation for myeloid leukaemia. Blood. 2004;103(4):1521-6. (Pubitemid 38168673)
15. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukaemia (AML) predicted by KIR and HLA genotypes. Blood. 2005;105(12):4878-84. (Pubitemid 40807317)
16. Sobecks RM, Ball EJ, Maciejewski JP, Rybicki LA, Brown S, Kalaycio M, et al. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant. 2007;39(7):417-24. (Pubitemid 46487307)
17. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukaemia. 2005;19(8):1446-51. (Pubitemid 41136340)
18. Kim HJ, Choi Y, Min WS, Kim TG, Cho BS, Kim SY, et al. The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukaemia. Transplantation. 2007;84(9):1082-91. (Pubitemid 350125348)
19. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
20. Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anaemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98(4):461-6. (Pubitemid 13116613)
21. Clausen J, Kircher B, Auberger J, Schumacher P, Ulmer H, Hetzenauer G, et al. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. Biol Blood Marrow Transplant. 2010;16(2):273-80.
22. Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogenic hematopoietic stem cell transplantation in patients with myeloid leukaemias. Blood. 2005;105(6):2594-600. (Pubitemid 40387064)
23. Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS, et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol. 2005;174(10):6540-5. (Pubitemid 40663849)
24. Bignon JD, Gagne K. KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol. 2005;17(5):553-9. (Pubitemid 41207961)
25. Schellekens J, Rozemuller EH, Petersen EJ, van den Tweel JG, Verdon-ck LF, Tilanus MG. Activating KIRs exert a crucial role on relapse and overall survival after HLA-identical sibling transplantation. Mol Immunol. 2008;45(8):2255-61.
26. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, et al. Anti-leukaemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for paediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009;113(13):3119-29.
27. Sivori S, Carlomagno S, Falco M, Romeo E, Moretta L, Moretta A. Natural killer cell expression the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood. 2011;117(16):4284-92.
28. Scquizzato E, Zambello R, Teramo A, Baesso I, Varotto S, Albergoni MP, et al. KIR/HLA-I mismatching and risk of relapse in paediatric patients undergoing non-haploidentical allogeneic haematopoietic stem cell transplantation. Pediatr Transplant. 2011;15(2):198-204.
29. Chen C, Busson M, Rocha V, Appert ML, Lepage V, Dulphy N, et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant. 2006;38(6):437-44. (Pubitemid 44340375)
30. Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, et al. Donor KIR genotype has a major influence on the rate of cytomeg-alovirus reactivation following T-cell replete stem cell transplantation. Blood. 2006;107(3):1230-2. (Pubitemid 43156330)
31. Gallez-Hawkins GM, Franck AE, Li X, Thao L, Oki A, Gendzekhadze K, et al. Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection. Biol Blood Marrow Transplant. 2011;17(11):1662-72.
32. Hadaya K, de Rham C, Bandelier C, Bandelier C, Ferrari-Lacraz S, Jendly S, et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant. 2008;8(12):2674-83.